Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models of solid tumor cell lines; IV injection disseminated models of hematopoietic cancer cell lines; 13 experimental metastasis models covering 7 cancer types

DLL3 related lung cancer PDX models, validated by RNA-Seq and IHC staining

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically …Read More >

Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) have emerged as key regulators of neuronal degeneration and axon growth.  WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry demonstrating the use of ligand- and structure-based drug design approaches to discover an amino-pyrazine chemical series of DLK and …Read More >

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to …Read More >

In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging assays for compound profiling.  We also showcase our recent publications describing the development of HBV antigen inhibitors and noncovalent inhibitors of the SARS-CoV-2 3C-like protease (3CLpro).  

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss. Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo. https://pubmed.ncbi.nlm.nih.gov/36089112/